Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aidan Power

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
CNS Drugs|August 5, 2018
Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human BrainJohn A Hey, Petr Kocis, Jakub Hort, et al.
Clinical Pharmacokinetics|February 5, 2025
Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer's DiseaseJohn A Hey, Jeremy Y Yu, Susan Abushakra, et al.
Clinical Pharmacokinetics|October 25, 2017
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's DiseaseJohn A Hey, Jeremy Y Yu, Mark Versavel, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 11, 2020
APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive declineSusan Abushakra, Anton P Porsteinsson, Marwan Sabbagh, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 15, 2024
APOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate in <i>APOE</i> ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristicsSusan Abushakra, Anton P Porsteinsson, Marwan Sabbagh, et al.
Drugs|June 20, 2024
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's DiseaseJohn A Hey, Susan Abushakra, Kaj Blennow, et al.
Drugs|September 28, 2025
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 TrialSusan Abushakra, Aidan Power, David Watson, et al.
CNS Drugs|December 1, 2025
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional TrialsSusan Abushakra, P Murali Doraiswamy, John A Hey, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
CNS Drugs|August 5, 2018
Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human BrainJohn A Hey, Petr Kocis, Jakub Hort, et al.
Clinical Pharmacokinetics|February 5, 2025
Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer's DiseaseJohn A Hey, Jeremy Y Yu, Susan Abushakra, et al.
Clinical Pharmacokinetics|October 25, 2017
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's DiseaseJohn A Hey, Jeremy Y Yu, Mark Versavel, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 11, 2020
APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive declineSusan Abushakra, Anton P Porsteinsson, Marwan Sabbagh, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 15, 2024
APOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate in <i>APOE</i> ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristicsSusan Abushakra, Anton P Porsteinsson, Marwan Sabbagh, et al.
Drugs|June 20, 2024
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's DiseaseJohn A Hey, Susan Abushakra, Kaj Blennow, et al.
Drugs|September 28, 2025
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 TrialSusan Abushakra, Aidan Power, David Watson, et al.
CNS Drugs|December 1, 2025
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional TrialsSusan Abushakra, P Murali Doraiswamy, John A Hey, et al.
Pageof 2